Shareholders Approve Massive Increase in Authorized Shares, Enabling Significant Future Dilution
IVF sits 72% above its 52-week low of $0.71 on light trading volume (0.3× avg).
Summary
INVO Fertility shareholders approved a substantial increase in authorized common and preferred stock, alongside the issuance of shares for warrants and an expanded stock incentive plan, signaling potential for significant future dilution.
Key Events · Financing and Capital Events · IVF
-
Authorized Shares Massively Increased
Shareholders approved increasing authorized common stock from 6.25 million to 250 million shares, and authorized 100 million shares of preferred stock, providing significant capacity for future equity raises.
-
Warrant Exercise Approved
Stockholders approved the issuance of up to 4,733,728 common shares upon the exercise of warrants from a private placement that closed on December 4, 2025, confirming a material dilutive event.
-
Stock Incentive Plan Expanded
The 2019 Stock Incentive Plan was amended to increase shares available for issuance thereunder to a total of 1,000,000 shares, approximately 10% of the total issued and outstanding stock on a fully-diluted basis.
Analysis · IVF · Industrial Applications And Services
The approval of a 40-fold increase in authorized common stock, from 6.25 million to 250 million shares, coupled with the authorization of 100 million preferred shares, provides INVO Fertility with substantial capacity for future equity raises. This move, while not immediately dilutive, creates a significant overhang and suggests the company anticipates needing to issue a large number of shares, potentially at lower prices, to fund operations or strategic initiatives. Additionally, the approval to issue nearly 4.73 million shares upon warrant exercise from a December 2025 private placement confirms a material dilutive event. The expansion of the stock incentive plan also adds to potential future dilution. For a micro-cap company, these approvals collectively indicate a strategy heavily reliant on equity financing, which could pressure the stock price.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVF was trading at $1.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.71 to $144.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.